Table 2 Antimicrobial treatments in patients with CRE BSI

CAZ-AVI-containing regimen

28 (29.8)

2/28 (7.1)

CAZ-AVI

3

0

CAZ-AVI + ATM

7

0

CAZ-AVI + ATM + tigecycline

10

0

CAZ-AVI + ATM + aminoglycoside

2

0

CAZ-AVI + ATM + polymyxin

2

1/2

CAZ-AVI + tigecycline

4

1/4

OAAs regimen

66 (70.2)

25/66 (37.9)

Tigecycline-containing regimens

44 (66.7)

17/44 (38.6)

Tigecycline + aminoglycoside

28

10/28

± carbapenem

Tigecycline + aminoglycoside

3

2/3

+fluoroquinolone

Tigecycline + fosfomycin

2

0

Tigecycline + ATM

1

0

Tigecycline ± carbapenem

10

5/10

Polymyxin-containing regimens

10 (15.2)

4/10 (40)

Polymyxin + tigecycline +

4

1/4

aminoglycoside/ fluoroquinolone

Polymyxin + tigecycline ± carbapenem

3

2/3

Polymyxin + tigecycline + ATM

2

0

Polymyxin alone

1

1/1

Others

12 (18.2)

4/12 (33.3)

Aminoglycoside ± carbapenem

9

4/9

Fluoroquinolone + carbapenem

2

0

Aminoglycoside + fluoroquinolone

1

0

Monotherapy ^a

25 (37.9)

13/25 (52.0)

Combination therapy ^b

41 (61.1)

12/41 (29.3)

Appropriate therapy started within 24 h

Yes

49 (52.1)

8/49 (16.3)

No

45 (47.9)

19/45 (42.2)

Appropriate therapy started within 48 h

Yes

83 (88.3)

22/83 (26.5)

No

11 (11.7)

5/11 (45.5)